Index

Note: Page numbers of article titles are in **boldface** type.

### A
- **Abstinence**
  - in genital herpes management, 436
- **Abuse**
  - sexual
  - childhood
    - sexual behavior effects of, 306–307
- **Antiviral therapy**
  - in genital herpes management, 436–437
- **Attitude(s)**
  - sexual behavior effects of, 304–305

### B
- **Bacterial STDs**
  - prevention and control of innovative approaches to, 513–540. See also *Sexually transmitted diseases (STDs), bacterial, prevention and control of, innovative approaches to.*
  - Bacterial vaginosis, 393–401. See also *Vaginosis, bacterial.*
- **Behavior(s)**
  - sexual. See *Sexual behavior.*
- **Behavioral interventions**
  - in bacterial STDs prevention and control, 514–520

### C
- **Cancer**
  - cervical
    - screening for, 447–452
  - Cervical HPV infection
    - oncogenic, 439–458. See also *Human papillomavirus (HPV) infection, cervical.*
  - Cervicitis
    - mucopurulent, 333–349. See also *Mucopurulent cervicitis (MPC).*
  - Cervix
    - anatomy and physiology of, 333–335
  - *Chlamydia trachomatis*
    - detection of
      - new specimen types for, 371–372
      - vaccines for, 478
    - Chlamydial infection
      - clinical overview of, 283
      - epidemiology of, 283–288
      - assessment of challenges to, 283
      - in special populations
        - estimates of, 285–286
        - microbiology of, 283
      - nucleic acid amplification tests for, 368–375. See also *Nucleic acid amplification tests, for chlamydia.*
      - prevalence of population-based estimates of, 283–285
      - reported cases of, 287
      - screening for in males
        - in bacterial STDs prevention and control, 522
        - surveillance for, 287
        - symptoms of, 287
    - Cluster tracing
      - in bacterial STDs prevention and control, 524, 527
    - Condom(s)
      - in genital herpes management, 436

---

0891-5520/05/$ - see front matter © 2005 Elsevier Inc. All rights reserved.
doi:10.1016/S0891-5520(05)00058-9
id.theclinics.com
Counseling
for patients with genital HPV infection, 467–472. See also Genital HPV infection, counseling for patients with.
for patients with genital HSV infection, 459–476. See also Genital HSV infection, counseling for patients with.
risk-reduction in STD management in MCOs, 502–503
Culture(s)
for gonorrhea, 376

D
Demography
sexual behavior effects of, 300–305
Direct smear examination
for gonorrhea, 375–376

E
Expectation(s)
sexual behavior effects of, 304–305

F
Fluoroquinolone(s)
mechanisms of action of, 354–357
Neisseria gonorrhoeae resistant to, 351–365. See also Neisseria gonorrhoeae, fluoroquinolone-resistant.

G
Genital HPV infection
counseling for patients with, 467–472 external genital warts and, 472
key messages in, 470–471
partners and, 472
pregnancy-related, 472
special considerations in, 471–472
described, 467
educational challenge of, 469–470
psychosocial aspects of, 467–469
Genital HSV infection. See also Herpes simplex virus (HSV) infection, genital. counseling for patients with, 459–467
Genital warts
external in genital HPV infection counseling for patients with, 472

GISP. See Gonococcal Isolate Surveillance Project (GISP).
Gonococcal Isolate Surveillance Project (GISP), 352
Gonorrhea
clinical overview of, 288
epidemiology of, 288–290
in special populations estimates of, 289
microbiology of, 288
nucleic acid amplification tests for, 375–379. See also Nucleic acid amplification tests, for gonorrhea.
prevalence of population-based estimates of, 288
reported cases of, 289–290
surveillance for, 289–290

H
Herpes simplex virus (HSV) infection
barriers to dialogue about, 460–461
counseling for patients with, 459–476
asymptomatic shedding in, 466
determination of length of infection in, 465–466
importance of, 466–467
in asymptomatic patients who test positive, 466
psychosocial adjustment and, 463–465
described, 427–428, 459–460
diagnosis of disclosure of, 435–436
diagnostic tests for characteristics of, 430
damaging effects of, 434
during pregnancy, 433–434
in general population, 434
in high-risk patients, 432–433
in partners, 432
reliability of, 430–431
serologic assays, 430–432
identification of, 429
management of, 427–438
antiviral therapy in, 436–437
condoms in, 436
selective abstinence in, 436
medical importance of, 428
problems associated with, 428–429
transmission of
management of, 435
talking with patients about, 461–463
vaccines for, 482–485

Herpes simplex virus (HSV) infection type 2
in HIV acquisition, 417–419

Herpes simplex virus (HSV) type 2
in HIV prevention, 421–422
in HIV spread, 417
in HIV transmission, 419
in outcomes of intervention trials for
STDs, 419–421
treatment of
impact on HIV progression, 422–423

Hierarchy
sexual behavior effects of, 305

Homosexual men
STDs in
in Western Europe and U.S., 311–331. See also Sexually transmitted diseases (STDs), in homosexual men, in Western Europe and U.S.

HPV infection. See Human papillomavirus (HPV) infection.

HSV infection. See Herpes simplex virus (HSV) infection.

Human immunodeficiency virus (HIV) infection
acquisition of
HSV type 2 in, 417–419
prevention of
HSV type 2 in, 421–422
progression of
HSV type 2 treatment impact on, 422–423
spread of
HSV type 2 in, 417
treatment of
HSV type 2 in, 419

Human immunodeficiency virus (HIV)/STDs interactions
development in, 415–425

Human papillomavirus (HPV) infection
cervical
epidemiology of, 439–447
natural history of, 439–447
oncogenic, 439–458
screening for, 447–452
diagnostic tests for, 452–453
vaccines for, 479–482

Hybridization

probe
for gonorrhea, 376

I
Infection(s). See also specific types.
sexually acquired
in women
Mycoplasma genitalium as, 407–408

Internet-based interventions
in bacterial STDs prevention
and control, 532

M
Managed care organizations (MCOs)
STD care in, 491–511. See also Sexually transmitted diseases (STDs), treatment of, in MCOs.
types of, 492

Mass treatment
in bacterial STDs prevention
and control, 529–532

Mental health
sexual behavior effects of, 306–307

Microbicide(s)
in bacterial STDs prevention
and control, 520–521

MPC. See Mucopurulent cervicitis (MPC).

Mucopurulent cervicitis (MPC), 333–349
causes of, 337–340
certainty related to, 344
defined, 335–337
epidemiology of, 335–337
management of, 342–344
future efforts related to, 344
nonchlamydial
nongonococcal, 340–342

Mycoplasma genitalium
as sexually acquired infection in
women, 407–408
PID due to, 407–413. See also Pelvic inflammatory disease (PID), causes of.

N
Neisseria gonorrhoeae
fluoroquinolone-resistant, 351–365.
See also Fluoroquinolone(s).
clinical significance of, 357–360
determinant mechanisms in, 354–357
epidemiology of, 357–360
Neisseria gonorrhoeae (continued)
future directions in, 360–361
prevalence of, 351–353
treatment of
principles in, 353–354
nucleic acid amplification tests for, 375
vaccines for, 478–479
Nucleic acid amplification tests
development of, 367–368
for chlamydia, 368–375
confirmation of positive tests, 372
epidemiologic effects of, 373–375
future of, 378–379
inhibitors of, 369–370
PCR, 368
professional organizations
recommendations, 373
strand displacement
amplification, 368
transcription mediated
amplification, 368–369
for gonorrhea, 375–379
cost-effectiveness studies in, 377
cultures, 376
diagnostic specimen pooling in
cost savings due to, 377–378
direct smear examination,
375–376
future of, 378–379
partnering in, 378
pelvic examination in, 377
probe hybridization, 376
sample of, 376–377

P
Parental notification laws
behavioral interventions for STDs and challenges to, 557
Partner therapy
expedited
in bacterial STDs prevention and control, 527–529
Patient education
in STD management in MCOs, 502–503
PCR. See Polymerase chain reaction (PCR).
Peer referral
in bacterial STDs prevention and control, 524, 527
Pelvic examination
in gonorrhea detection, 377
Pelvic inflammatory disease (PID)
causes of, 407–413
Mycoplasma genitalium, 407–413
described, 408–410
management of, 410–411
PID. See Pelvic inflammatory disease (PID).
Polymerase chain reaction (PCR)
for chlamydia, 368
Pregnancy
genital HPV infection during, 472
genital HSV infection during diagnostic tests for, 433–434
Probe hybridization
for gonorrhea, 376
Project RESPECT, 548–550
Q
Quality of care
of STDs in MCOs, 495
R
Risk-reduction counseling
in STD management in MCOs, 502–503
S
Selective mass treatment
in bacterial STDs prevention and control, 529–532
Sexual abuse
childhood
sexual behavior effects of, 306–307
Sexual behavior
changes in attitudes effects on, 304–305
changes in expectations effects on, 304–305
changes in structure of marriage and family effects on, 304
changes in values effects on, 304–305
childhood sexual abuse effects on, 306–307
demographic effects on, 300–305
global socio-political and economic structure effects on, 299–300
hierarchy effects on, 305
mental health effects on, 306–307
modern day influences on, 297–309
technology effects on, 305–306
Sexually acquired infections
in women
Mycoplasma genitalium as, 407–408
Sexually transmitted diseases (STDs)
bacterial prevention and control of innovative approaches to, 513–540
behavioral interventions, 514–520
case-finding–and treatment-related, 521–532
cluster tracing, 524, 527
expedited partner therapy, 527–529
female screening in medical care settings, 521
in unconventional locations, 522–523
Internet-based interventions, 532
male chlamydial screening, 522
mass treatment, 529–532
microbicides, 520–521
peer referral, 524, 527
rescreening, 523–524
behavioral interventions for, 541–562
behavioral models in, 545–548
case studies, 551–556
challenges of, 556–557
development of challenges in, 542–543
large-scale intervention studies, 550–551
objectives of, 548
parental notification laws related to challenges to, 557
problems associated with, 556–557
Project RESPECT, 548–550
sexual context impact on, 545
syphilis elimination, 552
Thai 100% Condom Program, 554–556
Uganda ABC Program, 553–554
health transition related to, 298
in homosexual men in Western Europe and U.S. epidemiology of changes in, 312–315
increase in, 311–331
biologic factors in, 315–317
demographic trends and, 317
high-risk sexual behavior and, 317–320
psychosocial contexts and, 322–325
reasons for, 315–325
sexual marketplace and, 320–322
intervention trials for outcomes of
HSV type 2 in, 419–421
prevalence of, 491–492
risk factors for assessment bias in, 543–545
sexual behavior and, 297–309. See also Sexual behavior.
treatment of in MCOs, 491–511
case reporting in, 503–504
clinical practice guidelines in, 494–495
described, 493–494
diagnostic testing in, 498–501
literature review methods in, 493
management of exposed sex partners, 504–505
patient education in, 502–503
quality of care, 495
risk assessment in, 495–497
risk-reduction counseling in, 502–503
screening in, 498–501
study of, 493–506
discussion of, 505–506
results of, 493–505
types of, 501–502
vaccines for acceptability of, 485
Chlamydia trachomatis, 478
future directions in, 485–486
HSV, 482–485
human papillomavirus, 479–482
Neisseria gonorrhoeae, 478–479
progress in, 477–490
Sexually transmitted diseases (STDs)/HIV interactions developments in, 415–425
Stages of Change Theory, 547
STDs. See Sexually transmitted diseases (STDs).
Strand displacement amplification for chlamydia, 368

Syphilis
  elimination of behavioral interventions for, 552

T
Thai 100% Condom Program, 554–556
Theory of Reasoned Action, 548–549
Transcription mediated amplification for chlamydia, 368–369
Trichomoniasis, 387–393
  clinical manifestations of, 388–390
  clinical overview of, 290
  complications of, 388–390
  diagnosis of, 390–392
  epidemiology of, 290–291, 387–388
  in special populations estimates of, 291
  microbiology of, 290
  prevalence of population-based estimates of, 291
  treatment of, 392–393
2001 Bethesda System, 444–445

U
Uganda Abstinence/Be Faithful/Use Condoms (Uganda ABC Program), 553–554

V
Vaccine(s)
  for STDs, 477–490. See also Sexually transmitted diseases (STDs), vaccines for.
Vaginosis
  bacterial, 393–401
    complications of, 396–399
    diagnosis of, 399–400
    epidemiology of, 393
    pathophysiology of, 393–396
    treatment of, 400–401
Value(s)
  sexual behavior effects of, 304–305

W
Wart(s)
  genital external
    in genital HPV infection counseling for patients with, 472